April 25, 2014 18:00 UTC

New Data Generated by ABL's Genomics Products to Be Presented at American Clinical Virology Symposium Annual Meeting

ASM Clinical Virology Symposium 2014

LUXEMBOURG--(BUSINESS WIRE)-- Advanced Biological Laboratories, S.A. (ABL) announced today that new clinical data generated by the company's genomics products, a full suite of products for genomic data management, analysis and interpretation in virology, will be presented at the 30th American Society of Microbiology (ASM) Clinical Virology Symposium (CVS) Annual Meeting taking place April 27-30, 2014 in Daytona. ABL and its partners and customers will present seven presentations.

"We are making tremendous progress toward a full recognition of the clinical utility of our Sanger and Next Generation Sequencing (NGS) products, ViroScore and DeepChek, and clinical patient management systems, TherapyEdge and HepatiC," stated Dr Chalom Sayada, chief executive officer of ABL. "We look forward to sharing this new data on HIV, HCV and HBV with the infectious diseases community at this year's CSV meeting".

"We are continuously building on our comprehensive and integrated product portfolio by adding new features and adding access to new scientific content which is guided by our collaboration with our partners and customers throughout the world," said Ronan Boulmé, VP R&D and Operations. "We believe these new findings will help advance patient care in clinical virology."

A schedule of the presentations is available at www.ablsa.com/company/news/daytona.pdf

About ABL:
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek® and HepatiC™, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products received CE-marking for IVD use. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping, and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. More at www.ablsa.com. All trademarks used or mentioned in this release are protected.


Dr Chalom Sayada, Tél. : (+352) 2638 8921

Source: Advanced Biological Laboratories